Cribstone Capital Management, LLC Lineage Cell Therapeutics, Inc. Transaction History
Cribstone Capital Management, LLC
- $169 Million
- Q4 2022
A detailed history of Cribstone Capital Management, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Cribstone Capital Management, LLC holds 88 shares of LCTX stock, worth $41. This represents 0.0% of its overall portfolio holdings.
Number of Shares
88
Previous 88
-0.0%
Holding current value
$41
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
136Shares Held
108MCall Options Held
8KPut Options Held
3K-
Broadwood Capital Inc New York, NY49.6MShares$23.3 Million1.86% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$4.49 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$4.19 Million0.0% of portfolio
-
Defender Capital, Llc.6.31MShares$2.97 Million1.19% of portfolio
-
Raffles Associates LP New York, NY5.64MShares$2.65 Million3.45% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $79.8M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...